HMGCR and melanoma: Additionally, using the PRISM screening portal [33], pronounced sensitivity to the HMGCR inhibitors lovastatin and simvastatin was found in some tumors, including RMS, melanoma, Ewing Sarcoma, hepatocellular carcinoma, and diffuse glioma (Figure 1E).